AWARD NUMBER: W81XWH-15-1-0598

TITLE: Development of Small Molecule Activators of Protein Phosphotase 2A (SMAPs) for the Treatment of Castration-Resistant Prostate Cancer

PRINCIPAL INVESTIGATOR: Stephen Plymate, M.D.

CONTRACTING ORGANIZATION: University of Washington
Seattle, WA  98104-2499

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Development of Small Molecule Activators of Protein Phosphatase 2A (SMAPs) for the Treatment of Castration-Resistant Prostate Cancer

Purpose: We hypothesize that our novel derivative DT-061 activates PP2A, downregulates key PP2A substrates, and confers anti-prostate cancer activity. The objectives of this proposal are to further probe the mechanism and activity of DT-061 in anticipation of advancing this novel approach to cancer treatment into the clinic. Scope of Research: Determine the effects of DT-061 on clinically relevant patient-derived xenograft models of prostate cancer, representing various disease states and resistance mechanisms. These models will be utilized to determine the effects of DT-061 on tumor growth and the pharmacodynamic effects of treatment.

Subject: Protein phosphatase 2A (PP2A) is among the most abundant serine threonine phosphatases in mammalian cells, a bona fide tumor suppressor, and a key negative regulator of critical oncogenic proteins including the androgen receptor (AR), Akt, Erk, and Myc. We have recently developed a series of small molecules that activate PP2A and thereby exert anticancer effects in cell culture and xenograft models. This proposal focuses on a third generation, orally bioavailable small molecule activator of PP2A (SMAP), DT-061, with improved potency and pharmacologic properties compared to our earlier series. Activation of PP2A represents a highly novel approach to cancer treatment that may coordinately downregulate the AR and other key PP2A regulated oncogenic pathways.

PP2A, androgen receptor, prostate cancer, small molecule, patient derived xenograft
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>5</td>
</tr>
<tr>
<td>4. Impact</td>
<td>7</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>8</td>
</tr>
<tr>
<td>6. Products</td>
<td>10</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>12</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>15</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>15</td>
</tr>
</tbody>
</table>
1. INTRODUCTION:

Subject: Protein phosphatase 2A (PP2A) is among the most abundant serine threonine phosphatases in mammalian cells, a bona fide tumor suppressor, and a key negative regulator of critical oncogenic proteins including the androgen receptor (AR), Akt, Erk, and Myc. Indeed, decreased PP2A activity and/or reduced expression of PP2A enzyme subunits has previously been demonstrated in multiple malignancies including prostate cancer. We have recently developed a series of small molecules that activate PP2A and thereby exert anticancer effects in cell culture and xenograft models. This proposal focuses on a third generation orally bioavailable small molecule activator of PP2A (SMAP), DT-061, with improved potency and pharmaceutical properties compared to our earlier series. We have demonstrated, as detailed in the application, that our SMAPS induce apoptosis in prostate cancer cells lines and dephosphorylate and degrade the AR. Activation of PP2A represents a highly novel approach to cancer treated that may coordinately downregulate the AR and other key PP2A regulated oncogenic pathways. This project represents a multi-disciplinary collaboration - the principal investigators have been working together on the development of these novel compounds for 3 years and bring the complementary expertise and experience necessary for successful completion of this project. Purpose: We hypothesize that our novel derivative DT-061 activates PP2A, downregulates key PP2A substrates, and confers anti-prostate cancer activity. The objectives of this proposal are to further probe the mechanism and activity of DT-061 in anticipation of advancing this novel approach to cancer treatment into the clinic. Scope of Research: Aim 1: Determine the effects of DT-061 on clinically relevant patient-derived xenograft models of prostate cancer, representing various disease states and resistance mechanisms (e.g., castration-sensitive and resistant, enzalutamide-sensitive and resistant, etc). These models will be utilized to determine the effects of DT-061 on tumor growth and the pharmacodynamic effects of treatment. Aim 2: Determine the effects of DT-061 on the phosphoproteome in vivo in tumors treated in Aim 1. Global phosphoproteomic profiling will be performed to define the critical phosphoproteomic perturbations. Aim 3: Probe the effects of DT-061 on the AR and other PP2A substrates in prostate cancer cells and demonstrate the effects occur in a PP2A-dependent manner. We will determine the impact of PP2A inhibition and proteosome inhibition on SMAP-induced perturbations of PP2A substrates.

2. KEYWORDS:

PP2A, androgen receptor, prostate cancer, small molecule, xenograft
3. ACCOMPLISHMENTS: The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.

What were the major goals of the project?
List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

<table>
<thead>
<tr>
<th>Specific Aim 1: Determine the effects of DT-061 on prostate tumor growth, and downstream markers of target engagement including AR expression, in vivo.</th>
<th>Timeline</th>
<th>Site 1</th>
<th>Site 2</th>
<th>Site 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subtask 1: Obtain IACUC approval</td>
<td>1-2</td>
<td></td>
<td></td>
<td>Dr. Plymate</td>
</tr>
<tr>
<td>Subtask 2: Implant LuCaP 35, LuCaP 35CR, LuCaP 35 abiraterone resistant, LuCaP 86.2, VCaP, MDVR-VCAP, LNCaP and LNCaP 95 tumors in SCID mice (288 mice). Treat with DT-061.</td>
<td>3-15</td>
<td></td>
<td></td>
<td>Dr. Plymate</td>
</tr>
<tr>
<td>Subtask 3: Analyze tumor tissues from mice in subtask 2. Frozen tissue for steroid levels by mass spec, DT-061 levels, AR-FL and AR-SV expression by qRT-PCR and protein. AR canonical and variant transcriptome expression by RNA-seq.</td>
<td>15-36</td>
<td></td>
<td></td>
<td>Dr. Plymate</td>
</tr>
<tr>
<td>Milestone(s) Achieved: Proof of concept that DT061 has antitumorigenic effects and</td>
<td>36</td>
<td></td>
<td></td>
<td>Dr. Plymate</td>
</tr>
</tbody>
</table>

What was accomplished under these goals?
For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

During the first year of this study IACUC and ACURO approvals were obtained. Our University of Washington 3 year IACUC renewal was also due July 29, 2016. This renewal was completed and submitted and approved July 29th. However, this also prompted an ACURO review of the 3 year renewal. This renewal has been submitted, inquiries are currently being answered, and we are waiting for approval. With permission of ACURO, mice have been purchased and LuCaP86.2 and LuCaP35 xenografts have been implanted. When they reach treatment size (~100-150mm³), gavage will be started with DT-061 and vehicle control.
What opportunities for training and professional development has the project provided?

Nothing to report

How were the results disseminated to communities of interest?

Nothing to report

What do you plan to do during the next reporting period to accomplish the goals?

During the next reporting period we will expect to have implanted LuCaP86.2, LuCaP35, LNCaP95, and VCaP tumors and have completed treatment of LuCaP86.2 and 35 tumors with analysis.
4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

Nothing To Report

What was the impact on other disciplines?

Nothing to report

What was the impact on technology transfer?

Nothing to report
What was the impact on society beyond science and technology?

Nothing to report

5. CHANGES/PROBLEMS:

No changes or problems to report

Actual or anticipated problems or delays and actions or plans to resolve them

Delay due to submission of IACUC 3 year renewal, which required a re-view by ACURO; delay of approximately 6 months.
### Changes that had a significant impact on expenditures

Nothing to report

### Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

### Significant changes in use or care of human subjects

**NA**

### Significant changes in use of biohazards and/or select agents

Nothing to report
6. PRODUCTS:

- **Publications, conference papers, and presentations**
  Report only the major publication(s) resulting from the work under this award.

  **Journal publications.**

  Nothing to report

  **Books or other non-periodical, one-time publications.**

  Nothing to report
Other publications, conference papers and presentations.

Nothing to report

- Website(s) or other Internet site(s)

Nothing to report

- Technologies or techniques

Nothing to report
• Inventions, patent applications, and/or licenses

Nothing to report

• Other Products

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and/or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:
• data or databases;
• physical collections;
• audio or video products;
• software;
• models;
• educational aids or curricula;
• instruments or equipment;
• research material (e.g., Germplasm; cell lines, DNA probes, animal models);
• clinical interventions;
• new business creation; and
• other.

Nothing to report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?
**Example:**

**Name:** Mary Smith  
**Project Role:** Graduate Student  
**Researcher Identifier (e.g. ORCID ID):** 1234567  
**Nearest person month worked:** 5

**Contribution to Project:** Ms. Smith has performed work in the area of combined error-control and constrained coding.

**Funding Support:** The Ford Foundation (Complete only if the funding support is provided from other than this award.)

---

**Name:** Stephen Plymate, MD  
**Project Role:** PI  
**Nearest person month worked:** 1  
**Contribution to Project:** Oversees all work for grant and prepares manuscripts.

**Name:** Cynthia Sprenger, PhD  
**Project Role:** Co-Investigator  
**Nearest person month worked:** 3  
**Contribution to Project:** Supervises experimental design, writes animal protocols, assists in data analysis, and assists with manuscripts

**Name:** Takumo Uo, PhD  
**Project Role:** Research Scientist  
**Nearest person month worked:** 6  
**Contribution to Project:** Assists in data analysis and preparation of manuscripts

**Name:** Kathryn Epilepsia  
**Project Role:** Research Scientist  
**Nearest person month worked:** 6  
**Contribution to Project:** Oversees all animal work, performs animal procedures and tissue collection  
**Funding Support:** NIH and DOD TIA award

**Name:** Yan Wang  
**Project Role:** Research Scientist  
**Nearest person month worked:** 6  
**Contribution to Project:** Assists with animal procedures and tissue collection
Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to report

What other organizations were involved as partners?

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:
Organization Name:
Location of Organization: (if foreign location list country)
Partner’s contribution to the project (identify one or more)
• Financial support;
• In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);
• Facilities (e.g., project staff use the partner’s facilities for project activities);
• Collaboration (e.g., partner’s staff work with project staff on the project);
• Personnel exchanges (e.g., project staff and/or partner’s staff use each other’s facilities, work at each other’s site); and
• Other.
8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: N/A

QUAD CHARTS: N/A

9. APPENDICES: N/A